of effects of AAC based on setting and types of aided AAC on outcome variables: An aggregate study of single-case research with individuals with ASD. Dev Neurorehabil. 2013 Oct 8PMID: 24102440; X-5 2144. Geier DA, Kern JK, Geier MR. A Comparison of the Autism Treatment Evaluation Checklist (ATEC) and the Childhood Autism Rating Scale (CARS) for the Quantitative Evaluation of Autism. J Ment Health Res Intellect Disabil. 2013 Oct;6(4):255-67. PMID: 23914277; X-5 2145. Gentile I, Bravaccio C, Bonavolta R, et al. Response to measles-mumps-rubella vaccine in children with autism spectrum disorders. In Vivo. 2013 May-Jun;27(3):377-82. PMID: 23606694; X-5 2146. Georgiades S, Szatmari P, Boyle M, et al. Investigating phenotypic heterogeneity in children with autism spectrum disorder: A factor mixture modeling approach. Journal of Child Psychology and Psychiatry. 2013;54(2):206-15. X-5 E-90 2147. Gershon ES, Grennan K, Busnello J, et al. A rare mutation of CACNA1C in a patient with bipolar disorder, and decreased gene expression associated with a bipolar-associated common SNP of CACNA1C in brain. Mol Psychiatry. 2013 Aug 27PMID: 23979604; X-5 2148. Ghaleiha A, Asadabadi M, Mohammadi MR, et al. Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol. 2013 May;16(4):783-9. PMID: 22999292; X-5 2149. Ghaleiha A, Ghyasvand M, Mohammadi MR, et al. Galantamine efficacy and tolerability as an augmentative therapy in autistic children: A randomized, double-blind, placebo-controlled trial. J Psychopharmacol. 2013 Oct 15PMID: 24132248; X-5 2150. Ghanizadeh A, Moghimi-Sarani E. A randomized double blind placebo controlled clinical trial of N- Acetylcysteine added to risperidone for treating autistic disorders. BMC Psychiatry. 2013;13:196. PMID: 23886027; X-5 2151. Gillespie-Smith K, Riby DM, Hancock PJ, et al. Children with autism spectrum disorder (ASD) attend typically to faces and objects presented within their picture communication systems. J Intellect Disabil Res. 2013 Apr 19PMID: 23600472; X-1, X-3, X-4 2152. Goetz CG, Stebbins GT, Chung KA, et al. Which dyskinesia scale best detects treatment response? Mov Disord. 2013 Mar;28(3):341-6. PMID: 23390076; X-5 2153. Gokey KM, Wilder DA, Welch T, et al. Fading a concurrent activity during self-control training for children with autism. J Appl Behav Anal. 2013 Aug 12PMID: 24114520; X-3 2154. Goldingay S, Stagnitti K, Sheppard L, et al. An intervention to improve social participation for adolescents with autism spectrum disorder: Pilot study. Dev Neurorehabil. 2013 Nov 8PMID: 24206240; X-5 2155. Goldman LE, Chu PW, Osmond D, et al. Accuracy of do not resuscitate (DNR) in administrative data. Med Care Res Rev. 2013 Feb;70(1):98-112. PMID: 22955698; X-5 2156. Golubchik P, Sever J, Weizman A. Reboxetine treatment for autistic spectrum disorder of pediatric patients with depressive and inattentive/hyperactive symptoms: An open-label trial. Clinical Neuropharmacology. 2013;36(2):37-41. X-1, X-3, X-5 2157. Graf-Myles J, Farmer C, Thurm A, et al. Dietary adequacy of children with autism compared with controls and the impact of restricted diet. Journal of Developmental and Behavioral Pediatrics. 2013;34(7):449-59. X-5 2158. Granovetter M. Let's talk therapy: treatments for children with autism. Lancet. 2013 Aug 31;382(9894):753. PMID: 23993177; X-1, X-2, X-3, X-4 2159. Grant PJ, Joseph LA,